Niagen Bioscience Inc (NAGE) Financial Statements

Income statement

Metric	TTM	2025	2024	2023	2022
Revenue
Total Revenue	129.1M	129.4M	99.6M	83.6M	72.0M
Cost of Revenue	46.2M	46.2M	38.0M	32.8M	29.3M
Gross Profit	82.9M	83.2M	61.6M	50.8M	42.8M
Operating Expenses
R&D Expense	6.5M	6.3M	6.0M	5.0M	4.8M
SG&A Expense	67.8M	62.6M	47.8M	51.4M	56.6M
General & Admin Expense	28.8M	27.1M	18.4M	25.0M	28.3M
Selling & Marketing Expense	39.0M	35.5M	29.5M	26.4M	28.3M
Other Expenses	—	—	—	—	—
Total Operating Expenses	74.3M	68.9M	53.9M	56.4M	61.4M
Cost and Expenses	120.5M	115.1M	91.9M	89.2M	90.7M
Operating Income (EBIT)	8.6M	14.3M	7.7M	(5.6M)	(18.6M)
Non-Operating
Interest Income	1.9M	2.1M	1.1M	661.0K	3.0K
Interest Expense	—	—	—	—	—
Net Interest Income	1.9M	2.1M	1.1M	661.0K	3.0K
Other Non-Op Income/Expense	8.4M	3.9M	1.1M	661.0K	2.1M
Non-Operating Income (excl Interest)	(8.0M)	(3.9M)	(1.1M)	(661.0K)	(2.1M)
EBT (Pre-Tax Income)	17.0M	18.2M	8.9M	(4.9M)	(16.5M)
Income Tax Expense	1.0M	810.0K	305.0K	—	—
Bottom Line
Net Income	16.0M	17.4M	8.6M	(4.9M)	(16.5M)
Earnings from Cont. Ops	16.0M	17.4M	8.6M	(4.9M)	(16.5M)
Earnings from Discont. Ops	—	—	—	—	—
Bottom Line Net Income	16.0M	17.4M	8.6M	(4.9M)	(16.5M)
Per Share
Basic EPS	$0.19	$0.22	$0.11	($0.07)	($0.24)
Diluted EPS	$0.19	$0.20	$0.11	($0.07)	($0.24)
Revenue Per Share	$1.63	$1.63	$1.25	$1.18	$1.05
Shares
Basic Shares Outstanding	79.3M	79.2M	79.7M	70.5M	68.9M
Diluted Shares Outstanding	82.5M	85.4M	79.7M	75.0M	69.7M
Profitability Metrics
EBITDA	18.5M	19.6M	10.3M	(3.2M)	(14.7M)
D&A	1.8M	1.4M	1.5M	1.7M	1.9M
EBIT	16.7M	18.2M	8.9M	(4.9M)	(16.5M)

As reported, in the filing currency · TTM sums the four latest quarters; MRQ is the latest quarter · Negatives in parentheses; a dash is a line the filing does not carry · Data as of Jun 1, 2026